Drug intelligence / Profile preview

gallium Ga 68-NOTA-3PTATE-RGD

Development stage: Phase 1
Lead developer: Peking Union Medical College Hospital
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration: Intravenous

Overview

Gallium Ga 68-NOTA-3PTATE-RGD is an investigational dual-targeted **gallium-68 PET radiopharmaceutical** developed for tumor imaging. It is a NOTA-chelated heterodimeric peptide comprising an octreotate-derived TATE moiety, which preferentially binds somatostatin receptor type 2, and an RGD moiety, which binds integrin alpha-V/beta-3. Following intravenous administration, it is intended to visualize and quantify tumors expressing either or both targets by PET/CT, including lung cancers and neuroendocrine neoplasms. It has been evaluated clinically by Peking Union Medical College Hospital, including in the registered NCT02817945 diagnostic imaging study and prospective imaging studies in gastroenteropancreatic neuroendocrine tumors. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gallium-ga-68-nota-3ptate-rgd))

Other names: 68Ga-NOTA-3P-TATE-RGD68Ga-NOTA-3PTATE-RGD

Targets

αVβ3 (Integrin αVβ3)SSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on gallium Ga 68-NOTA-3PTATE-RGD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium Ga 68-NOTA-3PTATE-RGD.

Explore the full profile